Interleukin-4 (IL-4) is produced within the bone marrow (BM) microenvironment either by nonresident circulating cells, namely T lymphocytes, mast cells, and basophils or by BM stromal cells. Importantly, IL-4 is able to induce proliferation of T-cell acute lymphoblastic leukemia (T-ALL) cells. 1 Therefore, IL-4 produced in the BM milieu might influence the progression Figure 1 For caption see next page.
Letters to the Editor of T-ALL by stimulating proliferation of tumor cells. However, the exact mechanisms by which IL-4 induces leukemia expansion remain unknown.
The effects of IL-4 on normal lymphocytes involve at least two signaling pathways, Jak/STAT and PI3K/Akt(PKB). 2 In addition, IL-4 activates the PI3K downstream target mTOR, which regulates cell cycle completion in activated mature T-cells. 3 Constitutive activation of mTOR has been reported in some T-ALL cases 4 and suggested to regulate viability, cell size and proliferation of tumor cells. However, leukemia cells depend not only on constitutive, cell-autonomous mechanisms but also on cues from the microenvironment to fully activate key signaling molecules that are essential for tumor expansion and decreased sensitivity to chemotherapy. 5, 6 Therefore, we investigated whether mTOR is involved in IL-4-mediated proliferation and growth of T-ALL cells. We previously showed that IL-4 promotes in vitro proliferation of a significant proportion of primary T-ALL samples. 1 Here, we selected 12 diagnostic patient samples that proliferated to IL-4 as assessed by 3 H-thymidine incorporation, to investigate the mechanisms of IL-4-driven T-ALL cell expansion. We first evaluated the effect of IL-4 on cell cycle progression by analyzing the DNA content of primary T-ALL cells by flow cytometry. IL-4 promoted the transition from G0/G1 to S-phase and G2/M in all five samples analyzed (Figure 1a) . IL-4 also induced cell size increase (cell growth) that paralleled the effect on cell cycle (Figure 1b and Supplementary Table 1) .
As proliferation may result not only from an effect on cell cycle progression but also from increased survival, we evaluated the effect of IL-4 on T-ALL cell viability. In accordance with previous studies, 7 we found that IL-4 had heterogeneous effects on T-ALL cell survival. IL-4 prevented T-ALL in vitro apoptosis in 6 of 12 cases (50%), promoted cell death in four (33%) and had no significant effects in two cases (17%; Supplementary Table 1 ). Nonetheless, IL-4-mediated proliferation occurred irrespectively of the effect on cell survival, and cell cycle progression was observed both in patients where IL-4 promoted viability and apoptosis (Supplementary Table 1 ). These data suggest that IL-4 promotes proliferation of primary T-ALL cells mainly through regulation of the cell cycle machinery.
Next we evaluated the mechanisms by which IL-4 mediated cell cycle progression in T-ALL cells. IL-4 did not affect the expression of cyclin-dependent kinases cdk6, cdk4 and cdk2 (Figure 1c) . In contrast, cyclins were upregulated by IL-4 in a sequential manner (Figure 1d ). The early G1 molecule cyclin D2 peaked around 12-24 h of culture with IL-4, whereas expression of cyclins E and A, which are associated with late G1 and S-phase, reached a plateau at later time points (48 and 72 h). These effects were paralleled by hyperphosphorylation of Rb, a critical substrate of cyclin/cdk activity in the cell (Figure 1e ), indicating that IL-4 induced cyclin/cdk activity. To confirm these results, we performed in vitro kinase assays with cdk4 and cdk2 immunoprecipitated from IL-4-stimulated primary T-ALL cells. IL-4 clearly augmented cdk activity (Figure 1f ). In addition, IL-4 induced the downregulation of the cdk inhibitor p27 kip1 (Figure 1g ). This event was mandatory for IL-4-mediated cell cycle progression, because forced expression of p27 kip1 completely abrogated IL-4-mediated proliferation ( Figure 1h) .
As mTOR-dependent signaling has been associated with regulation of cell cycle and size, we next evaluated whether IL-4 activated mTOR in the T-ALL cell line TAIL7, whose biological features are similar to those from primary leukemia cells. 8 IL-4 induced phosphorylation of mTOR downstream targets p70S6K, S6 and 4E-BP1 in TAIL7 cells (Figure 2a) . As expected, IL-4-mediated phosphorylation of these molecules was inhibited by treatment with the mTOR-specific antagonist rapamycin (Figure 2b ). These data strongly indicate that IL-4 activates mTOR signaling in T-ALL cells. To evaluate the functional consequences of IL-4-mediated mTOR activation, we cultured T-ALL cells with IL-4 in the presence of rapamycin. At the molecular level, inhibition of mTOR prevented IL-4-dependent p27 kip1 downregulation (Figure 2c ). Accordingly, rapamycin completely blocked IL-4-mediated proliferation (Figure 1h ), cell cycle progression (Figures 2d and e) and growth (Figures 2f  and g ) of both TAIL7 and primary T-ALL cells.
In summary, we demonstrated that IL-4 mediates proliferation of T-ALL cells through mTOR-dependent regulation of cell cycle progression. In showing that mTOR is activated by a BM microenvironmental factor that positively stimulates leukemia T-cells, our observations strengthen the emphasis on mTOR as a key molecular target in T-ALL, and suggest that the inhibition of IL-4 signaling may also have therapeutic potential in T-cell leukemia.
